Lawmakers, Drug Companies Cast Lifelines to Antibiotics Industry

Brian Gormley

October 8, 2020

A new bill seeks to spur antibiotic development, while drugmakers plan to invest nearly $1 billion in the struggling sector

Lawmakers and drug companies are seeking to rescue an antibiotics industry that is floundering despite its success in developing new medicines.

Several antibiotics companies have collapsed after struggling to sell their drugs, a testament to what experts call a broken system for paying for these medications—one that scares venture capitalists away and forces small companies, the industry’s lifeblood, to rely heavily on grants and nontraditional investors.

Read the full piece here.

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

The push for antibiotics to fight fast-evolving superbugs is snagging on a broken business model. Six startups have won Food and Drug…

Fighting AMR with a value and subscription model

The recent reintroduction of the Pasteur Bill seeks to address the global threat that antimicrobial-resistant (AMR) infections pose, one subscription…

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

Developing a new antibiotic can take as long as 15 years. But in as few as two, the target bug…

‘The Last of Us’ might be fiction, but fungi are a looming threat

Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed. A patient with leukemia undergoes…

Name
First Last
Email
Zipcode
Organization
Title
Comments
This field is for validation purposes and should be left unchanged.

Wall Street Journal

Lawmakers, Drug Companies Cast Lifelines to Antibiotics Industry

Brian Gormley

October 8, 2020

A new bill seeks to spur antibiotic development, while drugmakers plan to invest nearly $1 billion in the struggling sector

More

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

Pharmaceutical Technology

Fighting AMR with a value and subscription model

Fierce Biotech

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

PHARMAVOICE

‘The Last of Us’ might be fiction, but fungi are a looming threat

Sign up for the latest on fighting AMR